---
title: "Beam Therapeutics announces press release availability"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293603857.md"
description: "Beam Therapeutics announced it will present updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency at the ERS Congress 2026. The late-breaking oral presentation is scheduled for September 8, 2026, in Barcelona, accompanied by an investor webcast. This update coincides with Beam's preparation to initiate a pivotal cohort for BEAM-302, its lead liver-targeting genetic disease program."
datetime: "2026-07-23T11:05:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293603857.md)
  - [en](https://longbridge.com/en/news/293603857.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293603857.md)
generator: "portal-rs"
---

# Beam Therapeutics announces press release availability

-   Beam Therapeutics announced it will present updated Phase 1⁄2 data for BEAM-302 in alpha-1 antitrypsin deficiency at ERS Congress 2026. \* Late-breaking oral presentation scheduled for Sept. 8, 2026 in Barcelona; Beam plans a 7:00 a.m. ET investor webcast via here. \* Update comes as Beam prepares to initiate a pivotal cohort for BEAM-302, its lead liver-targeting genetic disease program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230700PRIMZONEFULLFEED9766769) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [BEAM.US](https://longbridge.com/en/quote/BEAM.US.md)

## Related News & Research

- [Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results](https://longbridge.com/en/news/295256769.md)
- [Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary](https://longbridge.com/en/news/294814748.md)
- [Beam Communications Declares Dividend for FY2026 Shareholders](https://longbridge.com/en/news/296546543.md)
- [Braga signs Barcelona’s Tommy Marques in EUR 11 million deal](https://longbridge.com/en/news/296630075.md)
- [Avalyn Pharma advances inhaled pirfenidone AP01 in Phase 2b MIST trial for progressive pulmonary fibrosis](https://longbridge.com/en/news/296823544.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**